Article
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Blood - 2 Apr 2009
Lin Katherine I, Tam Constantine S, Keating Michael J, Wierda William G, O'Brien Susan, Lerner Susan, Coombes Kevin R, Schlette Ellen, Ferrajoli Alessandra, Barron Lynn L, Kipps Thomas J, Rassenti Laura, Faderl Stefan, Kantarjian Hagop, Abruzzo Lynne V
Abstract excerpt
Although immunoglobulin V(H) mutation status (IgV(H) MS) is prognostic in patients with chronic lymphocytic leukemia (CLL) who are treated with alkylating agents or single-agent fludarabine, its significance in the era of chemoimmunotherapy is not known. We determined the IgV(H) somatic mutation status (MS) in 177 patients enrolled in a phase 2 study of fludarabine, cyclophosphamide, and rituximab (FCR) and in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.